摘要:
A suspension formulation for therapeutic use includes a non-aqueous, hydrophobic vehicle exhibiting viscous fluid characteristics, a dry particle formulation comprising a biomolecule dispersed in the vehicle, and a surfactant incorporated in at least one of the vehicle and dry particle formulation. A dry particle formulation includes an interferon, a buffer, a surfactant, and one or more stabilizers selected from the group consisting of a carbohydrate, an antioxidant, and an amino acid.
摘要:
A suspension formulation for therapeutic use includes a non-aqueous, hydrophobic vehicle exhibiting viscous fluid characteristics, a dry particle formulation comprising a biomolecule dispersed in the vehicle, and a surfactant incorporated in at least one of the vehicle and dry particle formulation. A dry particle formulation includes an interferon, a buffer, a surfactant, and one or more stabilizers selected from the group consisting of a carbohydrate, an antioxidant, and an amino acid.
摘要:
A suspension formulation for therapeutic use includes a non-aqueous, single-phase vehicle exhibiting viscous fluid characteristics and a particle formulation comprising an erythropoietin receptor agonist dispersed in the vehicle.
摘要:
A suspension formulation for therapeutic use includes a non-aqueous, single-phase vehicle exhibiting viscous fluid characteristics and a particle formulation comprising an erythropoietin receptor agonist dispersed in the vehicle.
摘要:
The present invention relates to a method of making a liposome composition. In particular, the invention relates to a method of making liposomes targeted to a specific cell receptor for delivery of a liposome-entrapped drug to the cell. In one embodiment, the process involves the incorporation of lipid-linkers to the surface of pre-formed liposomes, preferably at a higher temperature, followed by the conjugation of one or more temperature-sensitive ligands to the linkers associated with the liposome surface at a lower temperature to avoid deactivation of the temperature sensitive ligands. The present invention also is directed to a product prepared according to the foregoing process, and its use to treat subjects. The present invention is also directed to a kit containing lipid-linker, ligand and pre-formed liposome.